Otsuka Pharmaceutical Co. Ltd (Otsuka) - Articles and news items

New data show clinical benefit of Adacolumn in UC

Industry news / 24 May 2016 / Victoria White, Digital Content Producer

Prof. Dr. Axel Dignass said the data show that Adacolumn provided clinical benefit in steroid-dependent patients with UC with previous failure to biologics…

NICE recommends tolvaptan for patients with ADPKD

Industry news / 28 October 2015 / Victoria White

Tolavptan is the first-ever treatment shown to slow progression of the life-threatening condition…

Otsuka announces efficacy results for delamanid for extensively drug-resistant tuberculosis

Industry news / 16 July 2015 / Victoria White

Data from a post-hoc subset analysis of Phase IIb clinical trials suggests the potential efficacy of Otsuka’s delamanid for the treatment of XDR-TB…

New data released from QUALIFY study of aripiprazole once-monthly

Industry news / 24 June 2015 / Victoria White

Otsuka and Lundbeck have announced newly released subgroup analysis of data from the QUALIFY study of Abilify Maintena (aripiprazole once-monthly)…

Otsuka’s JINARC (tolvaptan) becomes first-ever treatment approved in Europe for adults living with ADPKD

Industry news / 27 May 2015 / Victoria White

The EC has granted marketing authorisation for tolvaptan for the treatment of ADPKD in adults who have chronic kidney disease (CKD)…


CHMP recommends JINARC® (tolvaptan) for approval in EU for treatment of autosomal dominant polycystic kidney disease

Industry news / 2 March 2015 / Otsuka Pharmaceutical Co. Ltd

Otsuka Pharmaceutical Co., Ltd. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended JINARC® (tolvaptan) for approval…

H. Lundbeck A/S Logo 60x60

Otsuka and Lundbeck´s brexpiprazole demonstrates statistically significant effects in New Phase III Studies in adult patients with schizophrenia

Industry news / 11 December 2014 / H. Lundbeck A/S

… presented at the American College of Neuropsychopharmacology annual meeting.

H. Lundbeck A/S Logo 60x60

Treatment with once-monthly Abilify Maintena® (aripiprazole) significantly reduces hospitalisation rates for patients with schizophrenia compared with daily oral antipsychotics

Industry news / 7 April 2014 / Lundbeck

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Europe Ltd. (Otsuka) announced results from the final analysis of a mirror-image study showing statistically significant reductions (p<0.0001) in total psychiatric hospitalisation rates in patients diagnosed with schizophrenia...

H. Lundbeck A/S Logo 60x60

Lundbeck and Otsuka initiate European launch of Abilify Maintena®, a once-monthly formulation for the treatment of schizophrenia

Industry news / 18 March 2014 / Lundbeck

Denmark is the first country in Europe where Abilify Maintena® is fully reimbursed and accessible to people diagnosed with schizophrenia…

H. Lundbeck A/S Logo 60x60
H. Lundbeck A/S Logo 60x60

NDA for aripiprazole depot formulation for maintenance treatment of adult patients with schizophrenia accepted

Industry news, News / 22 November 2011 / H. Lundbeck A/S (Lundbeck)

A NDA for investigational once-monthly aripiprazole depot formulation accepted…

H. Lundbeck A/S Logo 60x60


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...